The Experts below are selected from a list of 615 Experts worldwide ranked by ideXlab platform
Patrice Jaillon - One of the best experts on this subject based on the ideXlab platform.
-
pharmacokinetic and pharmacodynamic drug interactions between digoxin and Macrogol 4000 a laxative polymer in healthy volunteers
British Journal of Clinical Pharmacology, 1999Co-Authors: Isabelle Ragueneau, Jean Marie Poirier, Nathalie Radembino, Anne Buu Sao, Christian Funckbrentano, Patrice JaillonAbstract:Aims The aim of this study was to examine the bioequivalence between a single oral dose of digoxin administered alone and with a coadministration of Macrogol 4000 (a laxative polymer) in 18 healthy volunteers. Methods This was an open, randomised, two-way cross-over study, with a single dose oral administration of 0.5 mg digoxin administered alone or in combination with Macrogol 4000, 20 g day−1 during 8 days. Pharmacokinetics of digoxin, heart rate and PR ECG interval at rest were assessed. Results Macrogol 4000 coadministration was associated with a 30% decrease of digoxin AUC and a 40% decrease in its Cmax (P<0.05). Digoxin tmax and t1/2,z were not significantly altered. Heart rate and PR interval did not differ during the two therapeutic sequences, digoxin alone and digoxin in combination. Conclusions Macrogol 4000 coadministration interacts with single-dose digoxin pharmacokinetics. This is most likely due to a reduction of the intestinal absorption of digoxin. However, there was no consequence of this interaction on heart rate and AV conduction.
-
Pharmacokinetic and pharmacodynamic drug interactions between digoxin and Macrogol 4000, a laxative polymer, in healthy volunteers.
British journal of clinical pharmacology, 1999Co-Authors: Isabelle Ragueneau, Jean Marie Poirier, Nathalie Radembino, Anne Buu Sao, Christian Funck-brentano, Patrice JaillonAbstract:Aims The aim of this study was to examine the bioequivalence between a single oral dose of digoxin administered alone and with a coadministration of Macrogol 4000 (a laxative polymer) in 18 healthy volunteers. Methods This was an open, randomised, two-way cross-over study, with a single dose oral administration of 0.5 mg digoxin administered alone or in combination with Macrogol 4000, 20 g day−1 during 8 days. Pharmacokinetics of digoxin, heart rate and PR ECG interval at rest were assessed. Results Macrogol 4000 coadministration was associated with a 30% decrease of digoxin AUC and a 40% decrease in its Cmax (P
Yu.v. Zhyhal - One of the best experts on this subject based on the ideXlab platform.
-
Functional constipation at a young age. Place of Macrogol 4000 (Forlax) in the treatment
GASTROENTEROLOGY, 2009Co-Authors: A.e. Dorofeiev, M.m. Rudenko, Yu.v. ZhyhalAbstract:Background. Considering the wide prevalence of functional constipation (FC) at a young age, we set ourselves the task of comparing the effectiveness of osmotic laxative Macrogol 4000 (Forlax) in the treatment of FC in adolescents and young adults in the Ukrainian population. Materials and methods. We have examined 35 young adults aged 19 to 25 years (average age 24.10 ± 0.33 years) and 28 children in late adolescence aged 15 to 19 years (average age 15.90 ± 0.21 years). In the group of young adults, female patients slightly dominated (20/15), and among adolescents, both sexes were equally represented (14/14). It was an open-label, multi-center study. Patients with FC were monitored at the Kyiv gastrocenter and Kramatorsk Children’s Territorial Medical Association. The diagnosis of FC in the adult and adolescent groups was made based on the well-known Rome IV criteria. The frequency of bowel movements during the week was evaluated, as well as the shape of the stool according to the Bristol stool scale. The general state of health and severity of abdominal distention were evaluated on a 10-centimeter Visual analogue scale. Macrogol Forlax was administered as 10 g of powder dissolved in a glass of water once a day in the morning. With insufficient effect after 7 days of treatment, the dose was doubled. The duration of the drug use was 14 days. Results. After two weeks of treatment, the following results were obtained. The frequency of bowel movements was 4.36 ± 0.21 (p < 0.001) once a week, the shape of the stool according to the Bristol stool scale was 3.48 ± 0.22 (p
-
functional constipation at a young age place of Macrogol 4000 forlax in the treatment
Gastroenterology, 2009Co-Authors: A.e. Dorofeiev, M.m. Rudenko, Yu.v. ZhyhalAbstract:Background. Considering the wide prevalence of functional constipation (FC) at a young age, we set ourselves the task of comparing the effectiveness of osmotic laxative Macrogol 4000 (Forlax) in the treatment of FC in adolescents and young adults in the Ukrainian population. Materials and methods. We have examined 35 young adults aged 19 to 25 years (average age 24.10 ± 0.33 years) and 28 children in late adolescence aged 15 to 19 years (average age 15.90 ± 0.21 years). In the group of young adults, female patients slightly dominated (20/15), and among adolescents, both sexes were equally represented (14/14). It was an open-label, multi-center study. Patients with FC were monitored at the Kyiv gastrocenter and Kramatorsk Children’s Territorial Medical Association. The diagnosis of FC in the adult and adolescent groups was made based on the well-known Rome IV criteria. The frequency of bowel movements during the week was evaluated, as well as the shape of the stool according to the Bristol stool scale. The general state of health and severity of abdominal distention were evaluated on a 10-centimeter Visual analogue scale. Macrogol Forlax was administered as 10 g of powder dissolved in a glass of water once a day in the morning. With insufficient effect after 7 days of treatment, the dose was doubled. The duration of the drug use was 14 days. Results. After two weeks of treatment, the following results were obtained. The frequency of bowel movements was 4.36 ± 0.21 (p < 0.001) once a week, the shape of the stool according to the Bristol stool scale was 3.48 ± 0.22 (p < 0.001), the need for excessive straining was observed in 6 (17.1 %) patients, a feeling of incomplete defecation persisted in 4 (11.4 %) persons. The general state of health according the Visual analogue scale was 5.41 ± 0.30 cm (p = 0.008), the feeling of bloating — 2.07 ± 0.22 cm (p = 0.08). Conclusions. In the Ukrainian population, Macrogol (Forlax) has a significant laxative effect in both young adults and adolescents suffering from functional constipation. According to our data, the efficiency reached 85.7 % in adults, and 89.3 % in adolescents.
Isabelle Ragueneau - One of the best experts on this subject based on the ideXlab platform.
-
pharmacokinetic and pharmacodynamic drug interactions between digoxin and Macrogol 4000 a laxative polymer in healthy volunteers
British Journal of Clinical Pharmacology, 1999Co-Authors: Isabelle Ragueneau, Jean Marie Poirier, Nathalie Radembino, Anne Buu Sao, Christian Funckbrentano, Patrice JaillonAbstract:Aims The aim of this study was to examine the bioequivalence between a single oral dose of digoxin administered alone and with a coadministration of Macrogol 4000 (a laxative polymer) in 18 healthy volunteers. Methods This was an open, randomised, two-way cross-over study, with a single dose oral administration of 0.5 mg digoxin administered alone or in combination with Macrogol 4000, 20 g day−1 during 8 days. Pharmacokinetics of digoxin, heart rate and PR ECG interval at rest were assessed. Results Macrogol 4000 coadministration was associated with a 30% decrease of digoxin AUC and a 40% decrease in its Cmax (P<0.05). Digoxin tmax and t1/2,z were not significantly altered. Heart rate and PR interval did not differ during the two therapeutic sequences, digoxin alone and digoxin in combination. Conclusions Macrogol 4000 coadministration interacts with single-dose digoxin pharmacokinetics. This is most likely due to a reduction of the intestinal absorption of digoxin. However, there was no consequence of this interaction on heart rate and AV conduction.
-
Pharmacokinetic and pharmacodynamic drug interactions between digoxin and Macrogol 4000, a laxative polymer, in healthy volunteers.
British journal of clinical pharmacology, 1999Co-Authors: Isabelle Ragueneau, Jean Marie Poirier, Nathalie Radembino, Anne Buu Sao, Christian Funck-brentano, Patrice JaillonAbstract:Aims The aim of this study was to examine the bioequivalence between a single oral dose of digoxin administered alone and with a coadministration of Macrogol 4000 (a laxative polymer) in 18 healthy volunteers. Methods This was an open, randomised, two-way cross-over study, with a single dose oral administration of 0.5 mg digoxin administered alone or in combination with Macrogol 4000, 20 g day−1 during 8 days. Pharmacokinetics of digoxin, heart rate and PR ECG interval at rest were assessed. Results Macrogol 4000 coadministration was associated with a 30% decrease of digoxin AUC and a 40% decrease in its Cmax (P
A.e. Dorofeiev - One of the best experts on this subject based on the ideXlab platform.
-
Functional constipation at a young age. Place of Macrogol 4000 (Forlax) in the treatment
GASTROENTEROLOGY, 2009Co-Authors: A.e. Dorofeiev, M.m. Rudenko, Yu.v. ZhyhalAbstract:Background. Considering the wide prevalence of functional constipation (FC) at a young age, we set ourselves the task of comparing the effectiveness of osmotic laxative Macrogol 4000 (Forlax) in the treatment of FC in adolescents and young adults in the Ukrainian population. Materials and methods. We have examined 35 young adults aged 19 to 25 years (average age 24.10 ± 0.33 years) and 28 children in late adolescence aged 15 to 19 years (average age 15.90 ± 0.21 years). In the group of young adults, female patients slightly dominated (20/15), and among adolescents, both sexes were equally represented (14/14). It was an open-label, multi-center study. Patients with FC were monitored at the Kyiv gastrocenter and Kramatorsk Children’s Territorial Medical Association. The diagnosis of FC in the adult and adolescent groups was made based on the well-known Rome IV criteria. The frequency of bowel movements during the week was evaluated, as well as the shape of the stool according to the Bristol stool scale. The general state of health and severity of abdominal distention were evaluated on a 10-centimeter Visual analogue scale. Macrogol Forlax was administered as 10 g of powder dissolved in a glass of water once a day in the morning. With insufficient effect after 7 days of treatment, the dose was doubled. The duration of the drug use was 14 days. Results. After two weeks of treatment, the following results were obtained. The frequency of bowel movements was 4.36 ± 0.21 (p < 0.001) once a week, the shape of the stool according to the Bristol stool scale was 3.48 ± 0.22 (p
-
functional constipation at a young age place of Macrogol 4000 forlax in the treatment
Gastroenterology, 2009Co-Authors: A.e. Dorofeiev, M.m. Rudenko, Yu.v. ZhyhalAbstract:Background. Considering the wide prevalence of functional constipation (FC) at a young age, we set ourselves the task of comparing the effectiveness of osmotic laxative Macrogol 4000 (Forlax) in the treatment of FC in adolescents and young adults in the Ukrainian population. Materials and methods. We have examined 35 young adults aged 19 to 25 years (average age 24.10 ± 0.33 years) and 28 children in late adolescence aged 15 to 19 years (average age 15.90 ± 0.21 years). In the group of young adults, female patients slightly dominated (20/15), and among adolescents, both sexes were equally represented (14/14). It was an open-label, multi-center study. Patients with FC were monitored at the Kyiv gastrocenter and Kramatorsk Children’s Territorial Medical Association. The diagnosis of FC in the adult and adolescent groups was made based on the well-known Rome IV criteria. The frequency of bowel movements during the week was evaluated, as well as the shape of the stool according to the Bristol stool scale. The general state of health and severity of abdominal distention were evaluated on a 10-centimeter Visual analogue scale. Macrogol Forlax was administered as 10 g of powder dissolved in a glass of water once a day in the morning. With insufficient effect after 7 days of treatment, the dose was doubled. The duration of the drug use was 14 days. Results. After two weeks of treatment, the following results were obtained. The frequency of bowel movements was 4.36 ± 0.21 (p < 0.001) once a week, the shape of the stool according to the Bristol stool scale was 3.48 ± 0.22 (p < 0.001), the need for excessive straining was observed in 6 (17.1 %) patients, a feeling of incomplete defecation persisted in 4 (11.4 %) persons. The general state of health according the Visual analogue scale was 5.41 ± 0.30 cm (p = 0.008), the feeling of bloating — 2.07 ± 0.22 cm (p = 0.08). Conclusions. In the Ukrainian population, Macrogol (Forlax) has a significant laxative effect in both young adults and adolescents suffering from functional constipation. According to our data, the efficiency reached 85.7 % in adults, and 89.3 % in adolescents.
Nathalie Radembino - One of the best experts on this subject based on the ideXlab platform.
-
pharmacokinetic and pharmacodynamic drug interactions between digoxin and Macrogol 4000 a laxative polymer in healthy volunteers
British Journal of Clinical Pharmacology, 1999Co-Authors: Isabelle Ragueneau, Jean Marie Poirier, Nathalie Radembino, Anne Buu Sao, Christian Funckbrentano, Patrice JaillonAbstract:Aims The aim of this study was to examine the bioequivalence between a single oral dose of digoxin administered alone and with a coadministration of Macrogol 4000 (a laxative polymer) in 18 healthy volunteers. Methods This was an open, randomised, two-way cross-over study, with a single dose oral administration of 0.5 mg digoxin administered alone or in combination with Macrogol 4000, 20 g day−1 during 8 days. Pharmacokinetics of digoxin, heart rate and PR ECG interval at rest were assessed. Results Macrogol 4000 coadministration was associated with a 30% decrease of digoxin AUC and a 40% decrease in its Cmax (P<0.05). Digoxin tmax and t1/2,z were not significantly altered. Heart rate and PR interval did not differ during the two therapeutic sequences, digoxin alone and digoxin in combination. Conclusions Macrogol 4000 coadministration interacts with single-dose digoxin pharmacokinetics. This is most likely due to a reduction of the intestinal absorption of digoxin. However, there was no consequence of this interaction on heart rate and AV conduction.
-
Pharmacokinetic and pharmacodynamic drug interactions between digoxin and Macrogol 4000, a laxative polymer, in healthy volunteers.
British journal of clinical pharmacology, 1999Co-Authors: Isabelle Ragueneau, Jean Marie Poirier, Nathalie Radembino, Anne Buu Sao, Christian Funck-brentano, Patrice JaillonAbstract:Aims The aim of this study was to examine the bioequivalence between a single oral dose of digoxin administered alone and with a coadministration of Macrogol 4000 (a laxative polymer) in 18 healthy volunteers. Methods This was an open, randomised, two-way cross-over study, with a single dose oral administration of 0.5 mg digoxin administered alone or in combination with Macrogol 4000, 20 g day−1 during 8 days. Pharmacokinetics of digoxin, heart rate and PR ECG interval at rest were assessed. Results Macrogol 4000 coadministration was associated with a 30% decrease of digoxin AUC and a 40% decrease in its Cmax (P
